Company Deep Dive

Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.

View Deep Dive

LLY

STRONG BUY

Eli Lilly and Company · Healthcare · United States · $1.1T · Avg Vol: $4.0B/d

82
StockRank
Get insider-trade alerts
Q
79
V
16
M
81
P/E (TTM)
43.1x
ROE
107.5%
D/E
1.4x
Dividend %
0.5%
Dir. Trades · 180d
−$2.9M →
Buybacks · 180d
$2.4B →

COMPANY DESCRIPTION

Eli Lilly and Company is a global pharmaceutical powerhouse that discovers, develops, manufactures, and markets innovative medicines across key therapeutic areas such as diabetes, oncology, immunology, and neuroscience. Its wide competitive moat is built on a robust R&D pipeline, extensive patent protection for its blockbuster drugs, and a well-established global sales and distribution network. Eli Lilly is a leading innovator, recently achieving significant market success in diabetes and obesity treatments.

FINANCIAL SUMMARY (USD)

Year2022202320242025CAGRTTM2026E2027EFwd CAGR
Revenue28.5B34.1B45.0B65.2B31.7%72.2B85.4B98.7B23.0%
EPS6.575.8311.8023.0752.0%28.2334.4542.6936.0%
Shares950.2M899.4M897.5M894.8M-5.8%891.7M———
Debt16.2B25.2B33.6B42.5B37.8%43.4B———
Equity10.6B10.8B14.3B26.5B35.6%————
Op CF7.6B4.2B8.8B16.8B30.4%20.5B———
Inv CF-3.8B-7.2B-9.3B-11.0B—————
Fin CF-5.4B3.5B1.2B-2.2B—————
Loading 1Y...
PRICE (1Y)+12.4%
1,0641,1071,1501,1931,236May 27Jun 17Jul 9
SMA 50SMA 200
Close
$1,216.95
RSI (14)
69.1
52W High
$1,249.45
From 52W High
1.0%

SCORE BREAKDOWN

Quality
79
ROIC
38.4%98.2
ROE
107.5%99.4
GP/Assets
53.2%89.1
Op. Margin
49.4%98.4
FCF/Assets
8.1%80.9
Piotroski
782.9
Int. Cover
50.0x88.5
D/E Ratio
1.39x10.4
Current Ratio
1.50x25.8
Value
16
P/E (TTM)
43.1x25.4
EV/EBITDA
31.0x18.5
P/FCF
117.7x12.1
P/B
34.9x3.1
P/S
15.0x20.8
Div Yield
0.5%11.3
Momentum
81
52W High %
97%95.1
RS 6M
6%74.6
SMA 50/200
1.09x80.6
EPS Rev 4W
+0.8%82.0
EPS Rev 12W
+29.4%76.4
EPS Improve
+59%57.8
Q Growth
168%90.6

FUNDAMENTALS

Market Cap
$1.1T
P/E (Forward)
27.2x
Gross Margin
82.8%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of LLY are excluded.

TickerCompanyMkt CapStockRankSignal
LLYEli Lilly and Company(you)$1.1T82STRONG BUY
JNJ.DEJohnson & Johnson$609.8B77BUY
ABBV.MXAbbVie Inc.$438.5B82STRONG BUY
AZNAstraZeneca PLC$292.2B83STRONG BUY
NOVN.SWNovartis AG$297.7B85STRONG BUY
RO.SWRoche Holding AG$336.1B93STRONG BUY
NOVO-B.CONovo Nordisk A/S$214.5B84STRONG BUY
AMGNAmgen Inc.$193.4B83STRONG BUY
MRKMerck & Co., Inc.$317.8B93STRONG BUY
PFEPfizer Inc.$138.4B92STRONG BUY

Peer medians: ROE 2.7% · P/E 22.8x · Gross margin 47.5%

Eli Lilly and Company (LLY) — Stock Score Summary

Eli Lilly and Company (LLY) has a MoatMap StockRank of 82/100 based on Quality (79/100), Value (16/100), and Momentum (81/100) factor scores. The current signal is STRONG BUY.

Eli Lilly and Company is a global pharmaceutical powerhouse that discovers, develops, manufactures, and markets innovative medicines across key therapeutic areas such as diabetes, oncology, immunology, and neuroscience. Its wide competitive moat is built on a robust R&D pipeline, extensive patent protection for its blockbuster drugs, and a well-established global sales and distribution network. Eli Lilly is a leading innovator, recently achieving significant market success in diabetes and obesity treatments.

Key Financial Metrics

Price$1K
Market Cap$1.1T
P/E (TTM)43.11
P/E (Forward)27.16
Price/Book34.85
Return on Equity107.5%
Return on Invested Capital38.4%
Debt/Equity139.01
Gross Margin82.8%
Operating Margin49.4%
Revenue Growth55.5%
Dividend Yield0.5%
Free Cash Flow$9.2B

Eli Lilly and Company operates in the Drug Manufacturers - General industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Eli Lilly and Company’s (LLY) StockRank?
MoatMap’s StockRank for Eli Lilly and Company (LLY) is 82/100, with a Strong Buy signal. It is a composite of Quality (79), Value (16), and Momentum (81) factor ranks across MoatMap’s 20,000+ stock universe.
Does Eli Lilly and Company have an economic moat?
Eli Lilly and Company (LLY) has a Quality factor score of 79/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Eli Lilly and Company a buy, hold, or sell?
MoatMap’s current signal for Eli Lilly and Company (LLY) is Strong Buy, based on a StockRank of 82/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Eli Lilly and Company in?
Eli Lilly and Company (LLY) operates in the Healthcare sector, specifically the Drug Manufacturers - General industry (United States).
Browse all ranked stocksLLY deep dive reportAI ChampionsHow we score stocksSense-check another stock